BRISBANE, Calif., Dec. 4, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that the company’s lead PARP product candidate for triple negative breast cancer, BSI-201, will be the subject of a poster presentation at the 2008 annual San Antonio Breast Cancer Symposium (SABCS). The poster titled ``Triple Negative Metastatic Breast Cancer: A Phase 2, Multi-Center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C) With or Without BSI-201, a PARP Inhibitor’’ will be presented during the SABCS’s second poster session in Exhibit Hall B at 7:00 a.m. (CST) on Friday, December 12, 2008 at the Henry B. Gonzalez Convention Center, 200 E. Market Street in San Antonio, Texas.
